Liminatus Pharma, Inc. income statement LIMN

It recorded a net loss of $10.2 million. Diluted earnings per share were -$0.43.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Research and development
1
—
Selling, general and administrative
3
3
Operating income
-4
-3
Net income
-13
-10
Basic EPS
-0.36
-0.43
Diluted EPS
-0.36
-0.43
Weighted average shares, basic
35
24
Weighted average shares, diluted
35
24
Other measures
Depreciation and amortization
0
0
EBITDA
-4
-3
Interest coverage
-53.78x
-13.75x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
LIMN (Nasdaq), LIMNW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cerritos, CA
SEC filer status
, Emerging growth company
SEC CIK
1971387
Former names
Iris Parent Holding Corp. (until Feb 7, 2025)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.